Cas:887578-74-7 tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate

CAS.NO:887578-74-7

Synonyms:tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate

Molecular Formula:C₁₆H₂₃FN₂O₂

Molecular Weight:294.36400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:41.57000

Exact Mass:294.17400

LogP:3.25350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate Use and application,tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate technical grade,usp/ep/jp grade.

Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate manufacturer The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate supplier The monthly injection to suppress the virus that causes AIDS was aimed as an alternative to daily pills. tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate vendor With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. tert-butyl 3-[(4-fluorophenyl)methylamino]pyrrolidine-1-carboxylate factory The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.”